RU2015106916A - Полипептиды clostridium difficile в виде вакцины - Google Patents

Полипептиды clostridium difficile в виде вакцины Download PDF

Info

Publication number
RU2015106916A
RU2015106916A RU2015106916A RU2015106916A RU2015106916A RU 2015106916 A RU2015106916 A RU 2015106916A RU 2015106916 A RU2015106916 A RU 2015106916A RU 2015106916 A RU2015106916 A RU 2015106916A RU 2015106916 A RU2015106916 A RU 2015106916A
Authority
RU
Russia
Prior art keywords
seq
antigen
polypeptide
immunogenic composition
toxa
Prior art date
Application number
RU2015106916A
Other languages
English (en)
Russian (ru)
Inventor
Чезира ГАЛЕОТТИ
Розанна ЛЕУЦЦИ
Марияграция ПИЦЦА
Мария СКАРСЕЛЛИ
Меера УННИКРИШНАН
Мануэле МАРТИНЕЛЛИ
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201216748A external-priority patent/GB201216748D0/en
Priority claimed from GB201216749A external-priority patent/GB201216749D0/en
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of RU2015106916A publication Critical patent/RU2015106916A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2015106916A 2012-09-19 2013-09-19 Полипептиды clostridium difficile в виде вакцины RU2015106916A (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB201216748A GB201216748D0 (en) 2012-09-19 2012-09-19 Methods of treatment
GB201216749A GB201216749D0 (en) 2012-09-19 2012-09-19 Antigen combinations
GB1216748.2 2012-09-19
GB1216749.0 2012-09-19
PCT/IB2013/058673 WO2014045226A1 (en) 2012-09-19 2013-09-19 Clostridium difficile polypeptides as vaccine

Publications (1)

Publication Number Publication Date
RU2015106916A true RU2015106916A (ru) 2016-11-10

Family

ID=49725168

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015106916A RU2015106916A (ru) 2012-09-19 2013-09-19 Полипептиды clostridium difficile в виде вакцины

Country Status (13)

Country Link
US (1) US9932374B2 (enExample)
EP (1) EP2897637A1 (enExample)
JP (1) JP2015529677A (enExample)
KR (1) KR20150056540A (enExample)
CN (1) CN104582722A (enExample)
AU (1) AU2013319821A1 (enExample)
BR (1) BR112015004629A2 (enExample)
CA (1) CA2882620A1 (enExample)
IL (1) IL237172A0 (enExample)
MX (1) MX2015002485A (enExample)
RU (1) RU2015106916A (enExample)
SG (1) SG11201500980WA (enExample)
WO (1) WO2014045226A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2969952T3 (es) 2011-04-22 2024-05-23 Wyeth Llc Composiciones relacionadas con una toxina mutante de Clostridium difficile y sus procedimientos
BR122016023101B1 (pt) * 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
GB2525177A (en) * 2014-04-14 2015-10-21 New Royal Holloway & Bedford Vaccine
US10533036B2 (en) 2015-02-19 2020-01-14 Immune Biosolutions Inc Clostridium difficile toxins a and/or B antigen and epitope antibody, and pharmaceutical uses thereof
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
CA3102353A1 (en) 2018-06-19 2019-12-26 Glaxosmithkline Biologicals Sa Immunogenic composition
WO2021255690A2 (en) 2020-06-19 2021-12-23 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
GB202205833D0 (en) 2022-04-21 2022-06-08 Glaxosmithkline Biologicals Sa Bacteriophage

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU746859B2 (en) * 1997-06-20 2002-05-02 Imperial College Of Science, Technology And Medicine Immonogenic fragments of toxin a of clostridium difficile
KR20020097200A (ko) * 2000-03-21 2002-12-31 엘리트라 파마슈티컬즈, 인코포레이티드 원핵세포에서의 필수유전자의 동정
EP1292686A1 (en) 2000-06-07 2003-03-19 Smittskyddsinstitutet Gene expression cassette and its use
AU2002306849A1 (en) * 2001-03-21 2002-10-08 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
US20040029129A1 (en) * 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
AU2003299527A1 (en) * 2002-06-17 2004-06-07 Jimmy D. Ballard Mutant of clostridium difficile toxin b and methods of use
CA2693958A1 (en) * 2007-06-14 2008-12-18 Emergent Biosolutions, Inc. Chemically modified peptides with improved immunogenicity
AU2009219358A1 (en) * 2008-02-28 2009-09-03 3M Innovative Properties Company Antibodies to Clostridium difficile spores and uses thereof
US10046040B2 (en) * 2009-11-16 2018-08-14 University Of Maryland, Baltimore Multivalent live vector vaccine against Clostridium difficile-associated disease
JP2013512916A (ja) 2009-12-02 2013-04-18 タフツ ユニバーシティー 免疫原としてのＣｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅの無毒の組換えホロトキシン
EP2788022B1 (en) * 2011-12-08 2018-10-31 GlaxoSmithKline Biologicals SA Clostridium difficile toxin-based vaccine

Also Published As

Publication number Publication date
MX2015002485A (es) 2015-06-05
US9932374B2 (en) 2018-04-03
IL237172A0 (en) 2015-04-30
BR112015004629A2 (pt) 2017-11-21
AU2013319821A1 (en) 2015-02-26
CA2882620A1 (en) 2014-03-27
CN104582722A (zh) 2015-04-29
US20150315248A1 (en) 2015-11-05
EP2897637A1 (en) 2015-07-29
WO2014045226A1 (en) 2014-03-27
SG11201500980WA (en) 2015-04-29
JP2015529677A (ja) 2015-10-08
KR20150056540A (ko) 2015-05-26

Similar Documents

Publication Publication Date Title
RU2014127714A (ru) ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile
RU2508126C2 (ru) Композиции для иммунизации против staphylococcus aureus
BR112014030797A2 (pt) epítopo de peptídeo isolado, proteína recombinante, molécula de ácido nucléico isolada, vetor, célula hospedeira, método para preparar o epítopo de peptídeo ou mutante do mesmo, vacina de proteína, uso do epítopo de peptídeo ou mutante do mesmo, vacina de gene, uso da molécula de ácido nucléico, composição farmacêutica, anticorpo monoclonal e um fragmento de ligação ao antígeno do mesmo, linha de célula de hibridoma, kit, método para detecção da presença ou nível da proteína hbsag em uma amostra e uso do anticorpo monoclonal ou fragmento de ligação ao antígeno do mesmo
WO2014018858A3 (en) Multimeric fusion protein vaccine and immunotherapeutic
RU2017104529A (ru) Композиции neisseria meningitidis и способы их применения
MY173004A (en) Mycobacterial antigen vaccine
JP2020019816A (ja) ストレプトコッカス・スイス感染に対するワクチン組成物
JP2016504993A5 (enExample)
JP2012523246A5 (enExample)
SI2714910T1 (en) Immunogenic composition
JP2015529677A5 (enExample)
JP2015500827A5 (enExample)
CA2901888C (en) Influenza nucleoprotein vaccines
CN113577257B (zh) 细粒棘球绦虫EgTeg和EgFABP1多表位疫苗及应用
RU2016133598A (ru) Композиция микобактериального антигена
Sharma et al. Identification and immunogenic potential of B cell epitopes of outer membrane protein OmpF of Aeromonas hydrophila in translational fusion with a carrier protein
TWI693231B (zh) 豬胸膜肺炎放線桿菌重組毒素蛋白及其應用
WO2009074861A3 (en) Improved vaccine
NZ601980A (en) Recombinant proteins for use in vaccine, antibodies against said proteins, and diagnostic and therapeutic methods including the same
Walczak et al. Method for generation of peptide‐specific igy antibodies directed to Staphylococcus aureus extracellular fibrinogen binding protein epitope
CN104059134B (zh) 败血性巴氏杆菌毒素重组蛋白及其应用
CN106692963A (zh) 一种用于预防金黄色葡萄球菌感染和破伤风的联合疫苗
HRP20210458T1 (hr) Cjepivo za imunološki kompromitirane domaćine
Xiong et al. A porcine reproductive and respiratory syndrome virus (PRRSV) vaccine candidate based on the fusion protein of PRRSV glycoprotein 5 and the Toll-like Receptor-5 agonist Salmonella Typhimurium FljB
RU2015125699A (ru) Антигены и комбинации антигенов pseudomonas

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20171107